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Abstract
Background: Candida albicans is the most common cause of candidemia and other forms of invasive candidiasis.
Systemic infections due to C. albicans exhibit good susceptibility to fluconazole and echinocandins. However, the
echinocandin anidulafungin was recently demonstrated to be more effective than fluconazole for systemic Candida
infections in a randomized, double-blind trial among 245 patients. In that trial, most infections were caused by
C. albicans, and all respective isolates were susceptible to randomized study drug. We sought to better understand
the factors associated with the enhanced efficacy of anidulafungin and hypothesized that intrinsic properties of the
antifungal agents contributed to the treatment differences.
Methods: Global responses at end of intravenous study treatment in patients with C. albicans infection were
compared post-hoc. Multivariate logistic regression analyses were performed to predict response and to adjust for
differences in independent baseline characteristics. Analyses focused on time to negative blood cultures, persistent
infection at end of intravenous study treatment, and 6-week survival.
Results: In total, 135 patients with C. albicans infections were identified. Among these, baseline APACHE II scores
were similar between treatment arms. In these patients, global response was significantly better for anidulafungin
than fluconazole (81.1% vs 62.3%; 95% confidence interval [CI] for difference, 3.7-33.9). After adjusting for baseline
characteristics, the odds ratio for global response was 2.36 (95% CI, 1.06-5.25). Study treatment and APACHE II score
were significant predictors of outcome. The most predictive logistic regression model found that the odds ratio for
study treatment was 2.60 (95% CI, 1.14-5.91) in favor of anidulafungin, and the odds ratio for APACHE II score was
0.935 (95% CI, 0.885-0.987), with poorer responses associated with higher baseline APACHE II scores. Anidulafungin
was associated with significantly faster clearance of blood cultures (log-rank p < 0.05) and significantly fewer
persistent infections (2.7% vs 13.1%; p < 0.05). Survival through 6 weeks did not differ between treatment groups.
Conclusions: In patients with C. albicans infection, anidulafungin was more effective than fluconazole, with more
rapid clearance of positive blood cultures. This suggests that the fungicidal activity of echinocandins may have
important clinical implications.
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Despite the availability of new antifungal agents, systemic
candidiasis (i.e., candidemia and other forms of invasive
candidiasis) continue to contribute to excess morbidity,
greater mortality, prolonged hospitalizations, and
increased costs [1,2]. Epidemiological data demonstrate
that the frequency of Candida infections is rising [3-6],
along with an increase in the proportion of infections
caused by non-albicans Candida species that are intrinsi-
cally resistant or variably susceptible to fluconazole
[7-10]. However, C. albicans continues to be the most
common Candida species isolated [6,11,12].
The vast majority of C. albicans isolates from blood-
stream infections remain fully susceptible to fluconazole,
which has been the treatment of choice for these infec-
tions in most settings [13]. However, updated IDSA
guidelines now favor an echinocandin (anidulafungin,
caspofungin, or micafungin) as first-line treatment for
systemic candidiasis in moderately severe to severely ill
patients or those with prior azole exposure [14]. Echino-
candins have several potential advantages over flucona-
zole for the treatment of systemic candidiasis. They have
a broader spectrum of activity (encompassing flucona-
zole-resistant C. glabrata and C. krusei)a n de x h i b i t
potent fungicidal activity against most Candida species
[15-17]. Echinocandins are highly active in vitro against
C. albicans, with lower MICs than those of fluconazole
[8,18]. While fluconazole and the echinocandins have
similarly favorable safety profiles, the latter do not
require dose adjustment in patients with renal insuffi-
ciency [19-21].
A phase III, randomized, double-blind study compared
anidulafungin with fluconazole as primary treatment of
systemic candidiasis in adult patients infected with any
Candida species, except C. krusei [22]. Global response
rates at the end of IV study treatment in mITT patients
were significantly higher with anidulafungin (76%) than
fluconazole (60%). The superiority of anidulafungin was
questioned because of a potential center effect. However,
a number of robust statistical tests all failed to show the
presence of such an effect [22].
Of note, C. albicans was identified as the cause of
infection in the majority of cases (62%) and the difference
in global responses among this clinically important sub-
group was remarkable: 81% with anidulafungin versus
62% with fluconazole (p = 0.02) [22]. Since C. albicans
isolates were almost uniformly susceptible to fluconazole
[22], the excess failures in the fluconazole group could
not be attributed to antifungal resistance. However, due
to the lack of a multivariable analysis, it was unclear
whether these differences were potentially related to
unknown host factors. We therefore conducted a post-
hoc analysis using data collected from that trial, in order
to explore the factors associated with the better global
response of anidulafungin, specifically in patients with C.
albicans infections.
Methods
Study Design
The design of the original randomized clinical trial in
patients with confirmed candidemia or other forms of
invasive candidiasis has been described in detail previously
[22]. Enrolled patients were randomized to receive blinded
IV treatment with either anidulafungin or fluconazole;
after ≥ 10 days, the antifungal regimen could be changed
to open-label oral fluconazole. The primary endpoint was
global response at end of IV study treatment in the mITT
population. Other comparisons included time to negative
blood culture, rates of persistent infection at end of IV
study treatment (as assessed by the investigator based on
available clinical and microbiologic data), and 6-week
survival.
For the purposes of this post-hoc analysis, the study
database was reviewed to identify all patients with systemic
candidiasis caused by C. albicans only. Patients with non-
albicans Candida infections and mixed infections (C. albi-
cans and another concurrent pathogen) at baseline were
excluded from all subsequent analyses.
Microbiology
Screening blood cultures were obtained for all patients;
those cultures obtained > 24 hours before study entry
were repeated at baseline. Per the study protocol, blood
cultures were also to be obtained on Day 3, 7, and subse-
quently every 3 days until negative while on study medica-
tion. Additional blood cultures could be obtained when
clinically indicated, at the investigator’s discretion. For
patients with microbiologic evidence of infection from
sites other than blood, culture from the same site was
repeated as clinically indicated. All Candida isolates were
submitted to a reference laboratory, where MICs were
determined according to standard methods current at the
time of the study [23,24].
Statistical Analyses
The following analyses were conducted using data col-
lected from all patients with C. albicans infection-only
enrolled in the original clinical trial:
￿ In order to determine whether treatment arms dif-
fered significantly in terms of independent baseline
characteristics (see Table 1 for complete list, includ-
ing risk factors for systemic candidiasis), these char-
acteristics were compared by univariate analysis
using the chi-square test or Fisher’s exact test, as
appropriate. Exceptions were age and APACHE II
Reboli et al. BMC Infectious Diseases 2011, 11:261
http://www.biomedcentral.com/1471-2334/11/261
Page 2 of 8score, which were compared using the t-test. The
same methods were also used to identify all baseline
characteristics that differed between groups at the
p ≤ 0.2 level.
￿ In order to compare global response between treat-
ment arms after adjusting for baseline factors, all
those baseline characteristics that differed at the p ≤
0.2 level were placed into a multivariate logistic
regression model with global treatment success at
end of IV study treatment as the response variable.
Treatment was retained in the model and all vari-
ables were assessed for co-linearity.
￿ Thereafter, a best logistic regression model was
selected based on the Akaike Information Criterion
[25], in order to identify individual baseline variables
that significantly predicted treatment success at end
of IV study treatment. Adjusted odds ratios for treat-
ment and other variables were calculated, together
with their respective 95% CIs. Since this was an
exploratory post-hoc study, no adjustment for multi-
ple comparisons was made.
￿ In order to account for center-to-center variability,
this final model was then adjusted to also incorpo-
rate center as a random effect.
To compare the time to negative blood cultures, all
patients with a positive blood culture within 24 hours of
study entry (Day 1) were identified. Results of blood cul-
tures obtained per study protocol, and as clinically indi-
cated, were used in this analysis. The time in days to the
first documented sustained negative blood culture was
incorporated into a Kaplan-Meier analysis, and differences
between treatments were assessed using both the log-rank
test and the Wilcoxon test. Patients with invasive candi-
diasis confirmed through positive deep-tissue culture only
(i.e. without concomitant isolation of Candida from the
bloodstream) were excluded from this time-to-event ana-
lysis, since tissue cultures were not obtained according to
Table 1 Baseline characteristics of patients infected with C. albicans only
Characteristic Anidulafungin (n = 74) Fluconazole (n = 61) p
Sex, n (%) 0.858
Male 39 (52.7) 34 (55.7)
Female 35 (47.3) 27 (44.3)
Age (years)
a 0.097
b
Mean ± SD 54.6 ± 17.9 59.7 ± 17.1
Range 16-89 24-91
Race or ethnic group, n (%) 0.823
White 59 (79.7) 47 (77.0)
Black 7 (9.5) 8 (13.1)
Other 8 (10.9) 6 (9.8)
Risk factors for Candida infection, n (%)
Central venous catheter 54 (73.0) 47 (77.0) 0.691
Catheter removed within 24 h of study entry 70 (94.6) 56 (91.8) 0.731
Broad-spectrum antibiotics
a 43 (58.1) 44 (72.1) 0.106
Recent surgery 32 (43.2) 29 (47.5) 0.728
Recent hyperalimentation 17 (23.0) 12 (19.7) 0.678
Underlying malignancy 18 (24.3) 18 (29.5) 0.560
Immunosuppressive therapy 11 (14.9) 12 (19.7) 0.497
APACHE II score, n (%) 0.605
b
≤ 20 60 (81.1) 52 (85.2)
> 20 14 (18.9) 9 (14.8)
Mean ± SD (median) 13.7 ± 7.8 (12) 14.3 ± 6.4 (14)
Range 2-37 3-30
Absolute neutrophil count, n (%)
a 0.175
> 500/mm
3 73 (98.6) 57 (93.4)
≤ 500/mm
3 1 (1.4) 4 (6.6)
Site of infection, n (%) 0.343
Blood only 67 (90.5) 51 (83.6)
Deep tissue infection 7 (9.5) 10 (16.4)
a Baseline variables significant at the p ≤ 0.20 level.
b p value calculated using a t-test, assuming continuous distribution of this variable.
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incidence of persistent Candida infection was compared
using chi-square analysis. Kaplan-Meier analyses of survi-
val were generated and the difference in survival between
treatments at 6 weeks from study entry was assessed using
the log-rank test. All statistical analyses were conducted
using SAS version 8.2 (SAS Institute Inc., Cary, NC).
Results
Baseline Characteristics
The overall mITT population of 245 patients included
135 patients with C. albicans infection only; 74 of these
had been randomized to anidulafungin and 61 to flucona-
zole. Seventeen (12.6%) patients were enrolled at a single
study site; 28 sites (out of a total of 36) each enrolled <
5% of all mITT patients with C. albicans. Most presented
with candidemia only (90.5% vs 83.6% of patients treated
with anidulafungin and fluconazole, respectively; p = 0.34
by chi-squared test); the remaining patients had C. albi-
cans isolated from other normally sterile sites (including
peritoneal fluid/abdominal abscess or pleural fluid), with
or without concomitant isolation from the bloodstream.
Baseline characteristics for patients with C. albicans were
similar to those of the overall patient population [22].
There were no significant differences between the two
treatment groups in baseline demographic or clinical
characteristics, including age, sex, race, APACHE II
score, neutropenia, and other possible risk factors for
invasive Candida infection (Table 1). Central venous
catheters present at baseline were removed from all but
nine patients (four in the anidulafungin and five in the
fluconazole group).
Susceptibility of C. Albicans Isolates
Over 90% of blood cultures were collected at those time
points specified by the study protocol (± 1 day). The
median number of blood cultures collected per patient
was 16 in each arm. The C. albicans isolates tested were
uniformly susceptible to anidulafungin (MIC range,
≤ 0.002 to 0.03 μg/ml). All but one of the baseline
C. albicans isolates were susceptible to fluconazole (MIC
range, ≤ 0.06 to > 128 μg/ml). Of note, the single patient
with a fluconazole-resistant C. albicans isolate at baseline
(fluconazole MIC > 128 μg/ml) was randomized to
receive anidulafungin.
Efficacy
Global Response
The investigator-assessed global response rate at end of
IV study treatment was higher in patients with C. albi-
cans infections treated with anidulafungin compared to
fluconazole: 81.1% versus 62.3% (difference 18.8%; 95%
C I ,3 . 7 - 3 3 . 9 ) .T h ed i f f e r e n c ew a s statistically significant
at end of IV study treatment (p =0 . 0 2 ) ,a n dr e m a i n e d
significant at the end of all treatment and at the 2-week
follow-up (Figure 1). In the few patients with central
venous catheters at baseline who did not have these
removed, global response rates at end of IV study treat-
ment were 3/4 for anidulafungin and 3/5 for
fluconazole.
Univariate Analyses and Multivariate Logistic Regression
There were no significant (p ≤ 0.05) imbalances in any
baseline clinical or demographic characteristics between
the two treatment groups (Table 1). The significant dif-
ference in global response at end of IV study treatment
between the two treatment groups observed in the origi-
nal clinical trial for patients with C. albicans [22] was
maintained in the multivariate logistic regression model
after adjustment for all baseline variables that differed
between groups at the p ≤ 0.2 level (adjusted odds ratio,
2.36; 95% CI, 1.06-5.25). Specifically, these baseline vari-
ables were age, use of broad-spectrum antibiotics, and
absolute neutrophil count. In further analyses using the
Akaike Information Criterion to select a best model,
study treatment and APACHE II score (as a continuous
variable) were identified as significant and independent
predictors of global response at end of IV study treat-
ment in patients with invasive C. albicans infection.
From that analysis, after accounting for center as a ran-
dom effect, the odds ratio for study treatment was 2.60
(95% CI, 1.14-5.91) in favor of anidulafungin, and the
odds ratio for APACHE II score was 0.935 (95% CI,
0.885-0.987), with poorer responses associated with
higher baseline APACHE II scores. Additional analyses
adjusting for a potential center effect, i.e., grouping the
largest-enrolling center versus the rest and grouping all
centers that enrolled ≥ 5% of patients versus the rest,
resulted in very similar odds ratios (2.57 and 2.67, respec-
tively) and 95% CIs for the treatment effect.
Time to Negative Blood Culture
Forty-nine patients had positive blood cultures for
C. albicans within 24 hours of study entry. These positive
blood cultures cleared significantly more rapidly in
patients treated with anidulafungin than those on fluco-
nazole (Figure 2). In a Kaplan-Meier analysis, the time to
negative blood culture was significantly shorter for anidu-
lafungin compared with fluconazole (log-rank p <0 . 0 5 ) ;
median times to negative blood culture were 2 and 5
days, respectively. Persistent infection was reported in
two patients (2.7%) in the anidulafungin group compared
with eight (13.1%) in the fluconazole group (p < 0.05).
Survival
The proportion of patients who died during the 6-week
period from study entry was 20.3% (15/74) in the anidu-
lafungin arm and 21.3% (13/61) in the fluconazole arm;
the Kaplan-Meier estimates of survival at 6 weeks were
not significantly different between treatment groups (p =
0.842 by log-rank test). However, fewer deaths occurred
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than with fluconazole (4 vs 13; p =0 . 0 1b yc h i - s q u a r e
test).
Treatment Duration, Discontinuations, and Adverse Events
Both study drugs were well tolerated and the respective
safety profiles in patients with C. albicans infection only
were similar to those in the overall study population [22].
The mean duration of IV treatment was 13.8 days (range,
1-33 days) for anidulafungin and 12.6 days (range, 2-33
days) for fluconazole. The proportion of patients who
received open-label fluconazole after end of IV study
treatment was similar in both groups: 23/74 for anidula-
fungin (31.1%) and 21/61 (34.4%) for fluconazole.
The reasons for treatment failure and for discontinua-
tion of study treatment are summarized in Table 2.
Treatment discontinuations were more common in the
fluconazole arm than in the anidulafungin arm, primarily
because of worsening clinical status. Discontinuations
due to treatment-related adverse events were reported in
one patient receiving anidulafungin (elevated liver
enzymes) and four patients receiving fluconazole (wor-
sening candidemia [n = 1], elevated liver enzymes [n =
2], and rash [n = 1]).
Discussion
This study represents the first clinical analysis of differen-
tial response in patients with systemic candidiasis caused
by C. albicans to an echinocandin versus fluconazole,
conducted post-hoc in the relevant subpopulation from a
prospective clinical trial. The significance of this analysis is
that it enabled us to directly compare the efficacy of a fun-
gicidal with that of a fungistatic drug in patients with
C. albicans infections, without potential confounding by
differences in susceptibility. Despite all isolates of C. albi-
cans being susceptible to the antifungal agent received by
each patient, response to anidulafungin was significantly
greater than to fluconazole. Logistic regression analysis,
using the Akaike Information Criterion methodology,
demonstrated that study drug and baseline APACHE II
score were the principal independent variables determin-
ing this outcome, reflecting pharmacological and host fac-
tors, respectively. Study drug remained a significant
predictor of treatment success even after adjustment for
APACHE II scores and center variability, with an esti-
mated OR of 2.6. While there was notable variation in this
odds ratio, in part due to the relatively small sample size,
it remained significant from a statistical perspective and
should therefore be considered important. These results
suggest a pharmacological benefit of anidulafungin in the
treatment of systemic candidiasis due to C. albicans, since
no other factor, such as potential baseline imbalances and
center variability, was shown to have impacted the
outcome.
Understanding the factors determining clinical out-
comes in patients with C. albicans infections was
Figure 1 Global response rates at prespecified time points.
Figure 2 Kaplan-Meier estimates of time to first negative
blood culture. Analyses included patients with positive baseline
cultures for C. albicans (n = 49)
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common subpopulation in turn drove the treatment differ-
ences observed in the overall clinical trial [22]. Among
patients infected with C. albicans, anidulafungin resulted
in better global response at end of IV study treatment, at
the end of all treatment, and at the 2-week follow-up.
Moreover, patients treated with anidulafungin also had
more rapid eradication of yeast from the blood, as well as
lower rates of persistent C. albicans infection.
Whether the better response of anidulafungin in the
subpopulation of patients with systemic candidiasis caused
by C. albicans emerged as the result of an imbalance in
characteristics between the two treatment arms was not
evident from the previously available data. However, the
present analyses show that the efficacy differences were
not due to imbalances in baseline clinical or demographic
characteristics between treatment arms. There was also no
imbalance in the proportion of patients whose central
venous catheters remained in place during the study;
this factor is considered important, because removal or
replacement of central venous catheters may lead to better
outcomes [26,27]. Moreover, the lower response to fluco-
nazole could also not be explained by in vitro resistance.
Finally, first-line therapy with anidulafungin was identified
as a significant and independent predictor of successful
treatment outcome and remained so after adjustment for
APACHE II score.
Even though we did not specifically test fungicidality,
the recognized fungicidal properties of the echinocandin
may have contributed to this outcome. In fact, the more
rapid clearance of blood cultures and greater patient
survival during the early phase of therapy are consistent
with the pharmacodynamic properties of a fungicidal
agent [15,16,28-30]. Similar results have also been
observed in pre-clinical studies. For instance, a neutrope-
nic murine model of disseminated C. albicans infection
demonstrated that anidulafungin yielded significantly
greater reduction of fungal burden in the kidneys than
fluconazole [31] and, in a neutropenic rabbit model of
systemic candidiasis, anidulafungin cleared C. albicans
from tissues more effectively than fluconazole [32].
Organism-mediated tissue injury appears to be an intrin-
sic component of C. albicans pathogenesis [33-37], and
failure to quickly control candidemia can lead to dissemi-
nated infection and poor outcomes [38,39]. Considered
together, these results suggest that the enhanced fungici-
dal activity of echinocandins may have an impact on
treatment outcomes in invasive C. albicans infections.
Although there was a clear clinical benefit with anidula-
fungin, this did not translate into a difference in long-term
survival. We can merely speculate why this may have
occurred. It is possible that later deaths were attributable
to underlying illnesses rather than to systemic candidiasis.
In a matched case-controlled study among candidemia-
exposed and candidemia-unexposed patients, slightly less
than half of the overall mortality was caused by candide-
mia [2]. Another possible explanation is that optimal man-
agement of patients with invasive Candida infections
includes other interventions besides antifungal therapy,
and these factors were not controlled for in our study.
Table 2 Reasons for failure of and withdrawal from study medication
Anidulafungin Fluconazole
Observed failure
a 41 3
Clinical success and microbiologic failure
b 01
Clinical failure and microbiologic success 1 4
Clinical failure and microbiologic failure
b 37
Clinically indeterminate and microbiologic failure
b 01
Indeterminate response
c 10 10
Withdrawal from study medication 12 21
Due to adverse event
d 77
Due to withdrawal of consent 2 1
At investigator’s discretion 1 3
Worsening clinical status 2 9
Death within 24 hours of end of IV study treatment
b 47
Receipt of < 3 doses of study medication 1 1
a Observed failure was defined as treatment failure declared by the investigator to be clinical failure, microbiologic failure (i.e. positive findings on culture), or
both. In these patients mean time to failure was 16.8 days for anidulafungin and 8.9 days for fluconazole.
b Among those in whom microbiologic failure occurred, two of three patients in the anidulafungin group and eight of nine in the fluconazole group had
persistent infection. The other two patients in whom microbiologic failure occurred had superinfections.
c For the primary efficacy analysis, indeterminate response was treated as failure of global response. Patients could be considered to have an indeterminate
response for more than one reason.
d In the anidulafungin group, adverse events leading to discontinuation included sepsis (2), renal failure (1), elevated liver enzymes (1), multisystem organ failure
(1), cardiac failure (1), and hypoglycemia (1). In the fluconazole group, adverse events leading to discontinuation included renal failure (3), elevated liver enzymes
(2), cancer (1), and multisystem organ failure (1).
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better prognoses, thus making it more difficult to demon-
strate a survival benefit.
Our study has several potential limitations. Although the
comparison of global response in patients with C. albicans
infection was planned ap r i o r i , the analyses described in
this manuscript were performed post-hoc in a subset of
patients, albeit using prospectively collected data from a
double-blind, randomized clinical trial. Owing to the post-
hoc nature of these analyses, the two treatment groups did
not have the same sample size, which was not chosen to
be statistically powered. However, this slight disproportion
should not impact our overall results, as all relevant differ-
ences in baseline factors were adjusted for using multivari-
ate logistic regression; the odds ratio for the treatment
effect is thus corrected for any baseline imbalances. Of
note, despite incorporating a relatively large number of
baseline variables into the multivariate analyses, there may
have been unidentified confounding variables with a
potentially significant impact on response. Since no adjust-
ment was made for multiplicity, the results should be
interpreted with some caution. Another potential limita-
tion is the lack of daily blood culture collection during the
original trial, which precluded an accurate determination
of the exact time to negative blood culture; the corre-
sponding analysis should thus be interpreted with some
caution. This shortcoming is somewhat compensated for
by the fact that the vast majority of blood cultures were
collected on time points (± 1 day) prespecified by the
study protocol. Finally, extrapolation of our results to all
patients with systemic candidiasis due to C. albicans may
n o tb ea p p r o p r i a t e ,s i n c ew ef o c u s e do np a t i e n t sw i t h
C. albicans only and excluded those with mixed (albicans
and non-albicans) infections.
Conclusions
This analysis based on prospectively collected data from a
pivotal clinical trial confirms that anidulafungin had better
efficacy than fluconazole for the treatment of candidemia
or invasive candidiasis due to C. albicans. In these patients
with systemic candidiasis caused by fluconazole-suscepti-
ble C. albicans, anidulafungin was more effective than flu-
conazole in terms of better global response, faster
clearance of Candida from the bloodstream, and fewer
persistent infections.
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